申请人:Kyowa Kirin Co., Ltd.
公开号:EP3712129A1
公开(公告)日:2020-09-23
An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like:
[wherein, "A" represents optionally substituted heterocyclic diyl,
R1 represents hydrogen atom or optionally substituted lower alkyl,
R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group,
X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and
n1 and n2 are the same or different, and each represents 0 or 1].
本发明的目的是提供一种具有抗癌活性的α,β-不饱和酰胺化合物或其药学上可接受的盐或类似物。下式(I)代表的α,β-不饱和酰胺化合物或其药学上可接受的盐或类似物具有抗癌活性等:
[其中,"A "代表任选取代的杂环二基、
R1 代表氢原子或任选取代的低级烷基、
R2 代表任选取代的芳基、任选取代的环烷基、任选取代的脂肪杂环基团或任选取代的芳香杂环基团、
X代表-O-、-S-、-SO2-、-NRX1-(其中,RX1代表氢原子或低级烷基)、-CHRX2-(其中,RX2代表氢原子或羟基)、-CH=CH-、-CO-或-NH-CO-,以及
n1 和 n2 相同或不同,且各自代表 0 或 1]。